INVESTMENT SUBMISSION COVER PAGE
When submitting an investment opportunity to MABA, please first review our Investment Criteria
document – to ensure that there is a fit, and attach this cover page to your executive summary (which
should not exceed three pages).
Also, please be aware of MABA’s Presenting Company Warrant Grant Requirements:
MABA does not charge companies a cash fee to present. Nor does it get a free grant of equity.
In return for the opportunity to present to MABA, MABA receives from the company the chance to
invest in the company. While this chance may never have any value if the company is unable to achieve
its goals, should the company successfully accomplish what it has set out to do, the chance to invest
gives MABA the opportunity to benefit along with other investors.
Specifically, the company gives MABA the chance to invest up to $30,000 in the company, with the type
of security and the price MABA can buy determined by whatever investors accept in the next round.
MABA can take up to 7 years to make that investment. If MABA members do not invest at least
$125,000 in the company in the 12 month period following the company's presentation, MABA may
invest only up to $5,000 (but still for the type of security and at the price determined at the next round).
In reality, if the company is successful, a liquidity event would likely occur before the expiration of the 7
year time horizon, while chances are that the right may never be exercised and that it will have no value
- if the company does not succeed or there is no suitable liquidity event.
Please call us if you have any questions or concerns about this requirement. We look forward to
receiving your submission.
1.
Name of company (plus website – if any)
2.
Name of main contact (name, title, phone(s) & email)
3.
Location of company (if virtual, location of main
contact)
4.
Amount of money previously raised (total)
5.
Start-up date
6.
Date last round closed
7.
What was the valuation at the last round
8.
Amount of money being raised in current round
9.
Pre-money valuation for current round
10. When did current round begin & how much is
invested so far
11. Total investment funding anticipated to be raised
(including ALL rounds – past, present and future)
12. Describe non-dilutive or grant funding already
received or applied for
13. Describe the company’s product or service (one
sentence)
14. What is the market need for the company’s
product/service (one sentence)
15. Is this a product/service or a platform
16. If the company has developed a platform, what is
the first product/service to be marketed
commercially
17. What is/are your unfair advantage(s)?
18. If already selling – annual $ sales and number of
customers
19. Total addressable market (if platform – for first
product only)
20. Current development stage (of first product/service)
21. Sales and Go-to-Market Strategy
22. Describe status and scope of patent protection, if any
(number of applications, nature of claims, when
filed/granted)
23. Is there other IP?
24. Who owns the patents and other IP, if any?
25. Briefly describe how product/device will be
manufactured
26. Current & anticipated alliance partners (specifics)
27. FDA strategy, time to approval of optimal use, and
approval pathway
28. Time to reach major inflection point
29. Describe major inflection point – in words and $s
(e.g., exit, license…)
30. Key beneficiary(ies) (in addition to patients, who
benefits the most – financially and otherwise – from
your product/service, e.g., hospitals – if product
reduces/eliminates hospital never events)
31. Reimbursement strategy (one sentence)
32. Endorsement(s)/key supporters (specific names)
33. Professional advisors (specific names)
34. Describe all related party and special deals and
circumstances (grant backs to founders, special
licenses, etc.)
35. How can investors lose their money? What are the
biggest risks (competitive, regulatory, technical, etc.)
standing between the company and successful
commercialization and exit?
36. Executive pay – for each exec
37. Are any of the team members related (if so, how)?
38. Anticipated use of funds from this point forward
Please return this completed document - with your company name incorporated into the document
name, along with an executive summary, to Taryn Otto, [email protected]
Thank you.
Mid Atlantic Bio Angels (MABA)